CTT Pharma Secures U.S. Patent for Micelle-Based Nicotine, Vitamin, and Caffeine Oral Delivery Platform
核心洞察
CTT Pharmaceutical Holdings received U.S. patent approval for a continuation-in-part covering nicotine, vitamins, and caffeine delivery via its micelle technology, with issuance set for August 11, 2026.
The newly approved patent extends protection to multiple oral dosage forms including dissolvable strips, gum, pouches, lozenges, and dissolving tablets.
The company also signed a letter of intent with a U.S.-based testing company to conduct clinical trials for several potential nicotine products, paving a path toward independent market entry.
CTT Pharmaceutical Holdings, Inc. (搜索) (OTCQB:CTTH) has received formal approval from the U.S. Patent Office for a continuation-in-part (CIP) patent that broadens the protection around its micelle-based oral delivery technology. The patent, which will be officially issued on August 11, 2026, covers the delivery of nicotine, vitamins, and caffeine and extends the company's intellectual property to multiple dosage forms, including dissolvable strips, gum, pouches, lozenges, and dissolving tablets.
The CIP patent builds upon an earlier parent application by incorporating new subject matter and improvements. According to the company, this expansion strengthens its ability to develop and commercialize products across a range of oral delivery formats using its proprietary micelle platform.
"This new patent allows CTT Pharma the ability to use our technology to make dissolvable strips, gum, pouches, lozenges, and dissolving tablets," the company stated in its announcement. CTT emphasized that it will continue to invest in strengthening its patent portfolio, viewing intellectual property as a critical component of its business strategy.
Clinical Trial Pathway Advances
In a parallel development announced on June 22, 2026, CTT Pharma disclosed that it had signed a letter of intent (LOI) with an unnamed U.S.-based testing company to conduct clinical trials and testing for several potential nicotine products. The company indicated that a formal partnership would enable it to independently bring products to market in the United States using its patented technology.
"A partnership with this company would allow CTT the ability to independently go to market in the United States utilizing our patented technology," the company noted, adding that shareholders would be notified as further details become available.
Technology Platform
CTT Pharmaceutical Holdings specializes in oral drug delivery systems built around a micelle-based thin film platform. The technology is designed to offer rapid onset of action, enhanced patient convenience, and efficient absorption compared with traditional dosage forms. The company is targeting applications spanning pharmaceutical, therapeutic, and nutraceutical markets, with a stated focus on integrating scientific validation, scalable manufacturing, and regulatory preparedness to support long-term growth and product innovation.
The company has cautioned that forward-looking statements regarding plans, objectives, and potential partnerships involve risks and uncertainties, and actual results may differ materially from those expressed or implied.